[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589798":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":248,"collaborators":30,"id":250,"slug":30,"hasResults":251,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":251,"sex":257,"minAge":258,"maxAge":259,"enrollmentInfo":260,"targetDuration":30,"studyType":263,"phases":264,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":47,"whyStopped":30,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":287},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Depemokimab","EXPERIMENTAL","Participants will be administered depemokimab along with standard of care (SoC).",[13],"Drug: Depemokimab",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered placebo along with SoC.",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Depemokimab as a sterile liquid formulation will be administered.",[9],[26],"GSK3511294",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.",[15],null,[32],{"name":33,"affiliation":5,"role":34},"GSK Clinical Trials","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":42,"role":38,"phone":43,"phoneExt":30,"email":40},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[45,66,79,93,107,122,135,145,158,171,184,196,208,221,234],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"GSK Investigational Site","RECRUITING","Loxahatchee Groves","Florida","33470","United States",{"type":53,"coordinates":54},"Point",[55,56],-80.27977,26.68368,{"lat":56,"lon":55},[59,60,63],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":64,"role":65,"phone":30,"phoneExt":30,"email":30},"Neal Warshoff","PRINCIPAL_INVESTIGATOR",{"facility":46,"status":47,"city":67,"state":49,"zip":68,"country":51,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Miami","33155",{"type":53,"coordinates":70},[71,72],-80.19366,25.77427,{"lat":72,"lon":71},[75,76,77],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":78,"role":65,"phone":30,"phoneExt":30,"email":30},"Guillermo Somodevilla",{"facility":46,"status":47,"city":80,"state":81,"zip":82,"country":51,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Rock Hill","South Carolina","29732",{"type":53,"coordinates":84},[85,86],-81.02508,34.92487,{"lat":86,"lon":85},[89,90,91],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":92,"role":65,"phone":30,"phoneExt":30,"email":30},"Michael Denenberg",{"facility":46,"status":47,"city":94,"state":95,"zip":96,"country":51,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Corsicana","Texas","75110",{"type":53,"coordinates":98},[99,100],-96.46887,32.09543,{"lat":100,"lon":99},[103,104,105],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":106,"role":65,"phone":30,"phoneExt":30,"email":30},"John D Updegrove",{"facility":46,"status":47,"city":108,"state":109,"zip":110,"country":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Changsha","Hunan","410015","China",{"type":53,"coordinates":113},[114,115],112.97087,28.19874,{"lat":115,"lon":114},[118,119,120],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":121,"role":65,"phone":30,"phoneExt":30,"email":30},"Yingqun Zhu",{"facility":46,"status":47,"city":123,"state":124,"zip":30,"country":111,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Chengdu","Sichuan",{"type":53,"coordinates":126},[127,128],104.06667,30.66667,{"lat":128,"lon":127},[131,132,133],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":134,"role":65,"phone":30,"phoneExt":30,"email":30},"Xiao Liu",{"facility":46,"status":47,"city":123,"state":30,"zip":136,"country":111,"cosmosGeoPoint":137,"geoPoint":139,"contacts":140},"610041",{"type":53,"coordinates":138},[127,128],{"lat":128,"lon":127},[141,142,143],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":144,"role":65,"phone":30,"phoneExt":30,"email":30},"fuqiang Wen",{"facility":46,"status":47,"city":146,"state":30,"zip":147,"country":111,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Guangzhou","510150",{"type":53,"coordinates":149},[150,151],113.25,23.11667,{"lat":151,"lon":150},[154,155,156],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":157,"role":65,"phone":30,"phoneExt":30,"email":30},"Liping Wei",{"facility":46,"status":47,"city":159,"state":30,"zip":160,"country":111,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Hangzhou","310000",{"type":53,"coordinates":162},[163,164],120.16142,30.29365,{"lat":164,"lon":163},[167,168,169],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":170,"role":65,"phone":30,"phoneExt":30,"email":30},"Limin Wang",{"facility":46,"status":47,"city":172,"state":30,"zip":173,"country":111,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Jiangmen","529000",{"type":53,"coordinates":175},[176,177],113.08333,22.58333,{"lat":177,"lon":176},[180,181,182],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":183,"role":65,"phone":30,"phoneExt":30,"email":30},"Mingjiang Lin",{"facility":46,"status":47,"city":185,"state":30,"zip":30,"country":111,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Jiangxi",{"type":53,"coordinates":187},[188,189],105.19994,33.99934,{"lat":189,"lon":188},[192,193,194],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":195,"role":65,"phone":30,"phoneExt":30,"email":30},"Limin Dong",{"facility":46,"status":47,"city":197,"state":30,"zip":30,"country":111,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Mianyang",{"type":53,"coordinates":199},[200,201],104.68168,31.46784,{"lat":201,"lon":200},[204,205,206],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":207,"role":65,"phone":30,"phoneExt":30,"email":30},"Weiguo Xu",{"facility":46,"status":47,"city":209,"state":30,"zip":210,"country":111,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Qingyuan","511500",{"type":53,"coordinates":212},[213,214],113.03333,23.7,{"lat":214,"lon":213},[217,218,219],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":220,"role":65,"phone":30,"phoneExt":30,"email":30},"Dongbo Guangdong Tian",{"facility":46,"status":47,"city":222,"state":30,"zip":223,"country":111,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Zigong","643036",{"type":53,"coordinates":225},[226,227],104.77689,29.34162,{"lat":227,"lon":226},[230,231,232],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":233,"role":65,"phone":30,"phoneExt":30,"email":30},"Zhiping Deng",{"facility":46,"status":47,"city":235,"state":30,"zip":236,"country":237,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"Tokyo","140-8522","Japan",{"type":53,"coordinates":239},[240,241],139.69171,35.6895,{"lat":241,"lon":240},[244,245,246],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":30,"email":40},{"name":247,"role":65,"phone":30,"phoneExt":30,"email":30},"Masaharu Shinkai",{"type":249,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100589798",false,"NCT06959095","Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)","A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation","ENDURA -1","Inclusion Criteria:\n\n* Participants must be greater than or equal to (\\>=) 40 to less than or equal to (\\\u003C=) 80 years of age, at the time of signing the informed consent.\n* Elevated blood eosinophil count (BEC).\n* Moderate to severe COPD with frequent exacerbations, defined as:\n* A clinically documented history of COPD as defined by the American Thoracic Society\u002FEuropean Respiratory Society for at least 1 year\n* A post-bronchodilator forced expiratory volume in one second (FEV1)\u002Fforced vital capacity (FVC) ratio of less than (\\\u003C) 0.70 and a post- bronchodilator FEV1 \\>30 percent (%) and \\\u003C= 80% predicted normal values\n* A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening\n* COPD assessment test (CAT) score \\>=10 at Visit 1.\n* Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \\>=10 pack-years.\n* Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1.\n* Body mass index (BMI) \\>=16 kilogram per square meter (kg\u002Fm\\^2).\n* Male or eligible female participants.\n\nExclusion Criteria:\n\nThe following subjects are excluded:\n\n* Participants with a current or prior physician diagnosis of asthma.\n* Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.\n* Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.\n* Lung resection: Participants with a history of, or plan for lung volume reduction surgery \u002F endobronchial valve procedure.\n* Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1.\n* Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day.\n* Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension\n* Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \\[BiPAP\\] or Continuous Positive Airway Pressure \\[CPAP\\]).\n* Unstable cardiovascular disease or arrhythmia.\n* Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1).","ALL","40 Years","80 Years",{"count":261,"type":262},981,"ESTIMATED","INTERVENTIONAL",[265],"PHASE3","Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.",[268],"Pulmonary Disease, Chronic Obstructive",[9,26,270,271,272,273,274,275,276,15,277],"Eosinophilic phenotype","Chronic obstructive pulmonary disease","(COPD)","Moderate COPD","Severe COPD","Uncontrolled Moderate to Severe Chronic Obstructive Pulmonary Disease","Exacerbations","Type 2 inflammation","2025-10-06",{"date":280,"type":281},"2025-10-08","ACTUAL",{"date":283,"type":281},"2025-06-20",{"date":285,"type":262},"2029-08-20",{"name":5,"class":6},15]